Molecular Partners, in Collaboration with Orano Med, Announces Promising Preclinical Outcomes of Radio-DARPin Therapy MP0712 at SNMMI 2024

Molecular Partners MOLN, a clinical-stage biotech company specializing in the development of DARPin therapeutics, has recently shared encouraging preclinical data for MP0712, their leading radiotherapeutic candidate. Developed with strategic input from Orano Med, MP0712 is poised to be the pioneering candidate of Molecular Partners' Radio-DARPin Therapeutics (RDT) platform. Showcased at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024, the study highlights MP0712's potential in targeting Delta-like ligand 3 (DLL3) on cancer cells.

Positive Preclinical Data Highlights

The recent data spotlight MP0712 coupled with the radioisotope lead-212 (^212Pb), which specifically targets DLL3. The preclinical results are promising, demonstrating a substantial tumor-to-kidney ratio and an excellent biodistribution profile, a hallmark of an effective targeted radiotherapy. Furthermore, MP0712 indicated promising antitumor activity alongside a safety profile suggestive of a potentially effective therapeutic window.

Strategic Collaboration and Future Plans

Developed in partnership with Orano Med, MP0712 represents a blend of innovative approaches to fight cancer. As the first-in-class candidate of Molecular Partners' RDT platform, plans for a first-in-human study are on the horizon, with initial data eagerly anticipated by both the medical community and investors alike. The data thus far underscores the collaborative strength of Molecular Partners and Orano Med in developing cutting-edge cancer therapies.

The findings disclosed at the SNMMI 2024 conference bolster anticipation for the next phases of clinical development. With these positive preclinical outcomes, Molecular Partners and Orano Med are setting the stage for the progression of MP0712 into a potentially transformative treatment for patients battling DLL3-positive cancers.

Molecular, Partners, Orano, Med, MP0712, DLL3, Preclinical, Data, Radiotherapy, RDT, Lead-212, Antitumor, Safety, Studies